Navigation Links
'Gene signature' test diagnoses benign thyroid growths
Date:6/17/2013

A new genetic test accurately and consistently diagnoses benign growths, or nodules, on the thyroid gland, according to a study from Chile. The results will be presented Saturday at The Endocrine Society's 95th Annual Meeting in San Francisco.

"We have developed a 'gene signature' that effectively identifies benign thyroid nodules," said Hernan Gonzalez, MD, PhD, associate professor at the Pontifical Catholic University of Chile in Santiago. "This test is potentially useful to identify patients who do not require surgery."

The thyroid gland, located in the front of the neck, secretes thyroid hormone. This hormone is involved in many bodily processes, including turning food into energy. For unknown reasons, the thyroid gland sometimes develops small nodules. Although these nodules are extremely common and usually benign, a small number are cancerous, which makes screening tests essential.

In the United States this year, slightly more than 60,000 cases of thyroid cancer will be diagnosed and about 1,850 related deaths will occur, according to estimates from the American Cancer Society. Of these diagnosed cases, more than 45,000 will occur in women, who develop the disease more often than men.

Fortunately, thyroid cancer usually is curable. Screening for thyroid cancer involves using a thin needle to take a biopsy of the growth, called a fine needle aspirate biopsy, which is then analyzed for cancer cells.

The problem with the currently available screening test is that it often yields inconclusive results. In one-fifth to one-fourth of these tests, the results are unclear. In addition to causing anxiety among patients, inconclusive tests lead to repeated tests to rule out cancer, or even to surgery, given that cancer is present in about 25 percent of inconclusive cases. As a result, three out of four patients have unnecessary surgery, leading to rising treatment costs and the risk of possible complications related to unnecessary medical procedures.

The genetic test developed by the current study accurately identified benign nodules in nearly all samples analyzed. Specifically, the test differentiated between cancerous and non-cancerous tissue in 96 percent of thyroid samples.

"For the general public, this is important since it will offer a diagnostic tool that will avoid thousands of surgeries, with a major impact in health costs, eliminating potential surgical complications and the need for permanent thyroid hormone supplementation," Gonzalez said. "In addition, it should be widely available to local labs and hospitals and at a reasonable cost for the health system."

To develop the "gene signature" test, investigators conducted a literature search to identify 18 genes associated with thyroid cancer. They then selected 10 of these genes to develop a computer program that detects the presence of cancer in thyroid nodules. Using a sensitive DNA-amplifying test called polymerase chain reaction, they tested samples of thyroid nodules from 300 patients.

A biomedical research consortium in Santiago funded the study.


'/>"/>

Contact: Aaron Lohr
alohr@endocrine.org
240-482-1380
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. NIH awards $20 million over 5 years to train next generation of global health researchers
2. KRAS gene mutation and amplification status affects sensitivity to antifolate therapy
3. IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children
4. Researchers Find Gene Mutations That May Be a Key to Autism
5. Innovation Generation
6. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
7. Head, Body Lice Are Genetically Very Similar
8. Changes in gene expression may help explain high blood pressure in pregnancy
9. Certain Genetic Regions May Be Tied to Osteoporosis
10. Researchers ID Genes That May Determine Mental Illness
11. Target set on cancer gene MCL1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology: